Navigation Links
Eiger BioPharmaceuticals Appoints Paul Truex to Board of Directors
Date:8/17/2009

PALO ALTO, Calif., Aug. 17, 2009 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies with a focus on the NS4B Hepatitis C Virus (HCV) protein, announced today the appointment of Paul Truex to its Board of Directors.

Truex is the founder, President and CEO of Anthera Pharmaceuticals - a private pharmaceutical company focused on the development of anti-inflammatory products for life threatening cardiovascular and pulmonary diseases. Previously' he was Founder, President and CEO of Peninsula Pharmaceuticals where he negotiated both of Peninsula's anti-infective product agreements with Shionogi & Co.' Ltd. and Takeda Chemical Industries respectively. Peninsula was acquired by Johnson & Johnson in 2005 for $245 million. Previously, Mr. Truex held positions at Versicor (Vicuron), which was acquired by Pfizer for $1.9 billion, and at Eli Lilly. Mr. Truex obtained his M.B.A. in Marketing and Finance from Indiana University and a B.A. Degree in International Economics from the University of Waterloo.


"We are delighted to have Mr. Truex join Eiger's Board as an Independent Director," said David Cory, President and CEO of Eiger. "Paul will bring valuable experience to our corporate strategy and development as we advance both preclinical and clinical programs at Eiger."

"The combination of newly discovered HCV targets along with clinical and preclinical small molecule inhibitors already identified by Eiger make this a very exciting opportunity in the infectious disease space," said Paul Truex. "I'm looking forward to working with the Eiger board and management team to build a successful company."

Eiger BioPharmaceuticals recently announced the acquisition of exclusive license to novel HCV technology discovered in the labs of Stanford scientist and Eiger Founder Dr. Jeffrey Glenn, MD, PhD. This technology
'/>"/>

SOURCE Eiger BioPharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors
2. Eiger BioPharmaceuticals Raises $7.1 Million A Round
3. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
8. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
9. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
10. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
11. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... RI (PRWEB) January 22, 2015 Protocol ... , The growing team of brand-neutral, independent consultants, Protocol ... Philip Rogers explained that over the years, his company ... , Moroso, Town of Plainfield, as well as others. ...
(Date:1/22/2015)... Boston, MA (PRWEB) January 22, 2015 ... systems, is pleased to announce an exciting product from a ... of motion analysis solutions over the past 15 years, with ... industries. Most recently, their 3D IMU system (inertial measurement unit), ...
(Date:1/22/2015)... Switzerland (PRWEB) January 22, 2015 Selexis ... characterized mammalian Research Cell Banks (RCBs) used for drug ... Research Cell Banks will include Next-Generation Sequencing ... genetic architecture de-risks biologic manufacturing by ensuring the integrity ...
(Date:1/22/2015)... SAN DIEGO , Jan. 22, 2015   ... company, and Sequenom, Inc. (NASDAQ: SQNM ... a development agreement for next generation noninvasive prenatal ... Cypher,s genome interpretation technology, called Mantis™, to advance ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 23D Motion Capture Just Got Easy 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4
... Kits, Water ... Filters and Reusable Bottles, MONROVIA, Calif., Sept. 12 ... the minds of consumers who fear the impact of,bottled water on ... Testing has assembled a family of products on its website, http://www.discovertesting.com, ...
... New Jersey, September 12, Rosetta Genomics Ltd. ... of microRNA-based diagnostics and therapeutics, announced,today the ... present AACR,s,upcoming Molecular Diagnostics in Cancer Therapeutic ... Rosetta Genomics,unique microRNA-based technologies and current development ...
... BARCELONA, Spain, Sept. 12 Elekta is pleased ... planning and,performing Volumetric Intensity Modulated Arc Therapy (VMAT)*. ... featured in the Elekta booth at,this year,s European ... September 8-13, 2007. Performing VMAT with Elekta,enables helical- ...
Cached Biology Technology:Discover Testing Settles the Drinking Water Debate: Tap vs. Bottled 2Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference 2Elekta Displays Complete Volumetric Intensity Modulated Arc Therapy Solutions at ESTRO 2Elekta Displays Complete Volumetric Intensity Modulated Arc Therapy Solutions at ESTRO 3
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and ... the addition of the "Global Wearable Technologies ... Growth, Share, Overview, Trends and Forecast 2014-2020" ... Wearable Technologies are smart devices that can be ...
(Date:12/22/2014)... 22, 2014 Research and Markets ( ... "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides ... and fingerprinting markets. Watermarking aims to control and ...
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the ... the post-password and Internet of Things era, today announced ... The venture round was led by Metamorphic Ventures with ... Venture Partners, VegasTechFund, and others.  LaunchKey has raised $4 ...
Breaking Biology News(10 mins):Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... for even the most diligent dieters. But are weekends ... and Quinnipiac University in Hamden, Conn., found that weekend ... a University of Pittsburgh professor of marketing and associate ... School of Business, and his coauthor, Adwait Khare, Quinnipiac ...
... world meet in Copenhagen from December 7󈝾 for the United ... of Delaware are taking a leading role. A special day ... housed at UD, is being set aside during the negotiations ... Day, to be held Dec. 14, will highlight the direct ...
... additional brush strokes to the revolutionary new image now emerging ... cord. Their report, which suggests a key role for astrocytes ... online in ACS, Journal of Proteome Research , a ... point out that nearly everyone viewed astrocytes the most ...
Cached Biology News:Oceans day at International Climate Change Conference 2
Request Info...
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient vir...
...
Request Info...
Biology Products: